AstraZeneca Appoints New Head of Oncology
January 12, 2017
Following the departure in December, Mondher Mahjoubi, who left to become CEO of Innate Pharma (Marseille, France), AstraZeneca (AZ) has announced it has appointed Dr. Jamie Freedman as its new head of oncology. Dr. Freedman joins from AZ subsidiary MedImmune, where he was senior vice president of global clinical development, with responsibility for leading AstraZeneca's biologics portfolio. Prior to this, Dr Freedman held R&D leadership roles at GlaxoSmithKline and OPKO Health, and was formerly president and CEO of biotech Locus Pharmaceuticals.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
